Travis Steed
Stock Analyst at Barclays
(0.98)
# 1944
Out of 5,329 analysts
95
Total ratings
44.26%
Success rate
3.76%
Average return
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
BDX Becton Dickinson | Maintains: Overweight | 279 261 | 169.54 | 53.95% | 8 | Apr 7, 2025 | |
PEN Penumbra | Initiates Coverage On: Buy | 320 | 291.69 | 9.71% | 1 | Mar 14, 2025 | |
ABT Abbott Laboratories | Maintains: Strong Buy | 133 150 | 131 | 14.5% | 5 | Mar 10, 2025 | |
SOLV Solventum | Maintains: Neutral | 80 85 | 65.72 | 29.34% | 3 | Feb 26, 2025 | |
EW Edwards Lifesciences | Upgrades: Buy | 82 90 | 75.33 | 19.47% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 32 | 16.32 | 96.08% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 42 45 | 30.63 | 46.91% | 5 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underperform | 480 45 | 11.21 | 301.43% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 315 | 374.51 | -15.89% | 4 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 365 295 | 250.38 | 17.82% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 16 | 16.5 | -3.03% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underperform | 51 28 | n/a | n/a | 1 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underperform | 45 33 | 19.99 | 65.08% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 120 160 | 101.89 | 57.03% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 300 315 | 517.45 | -39.12% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 335 275 | n/a | n/a | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underperform | 8 | 3.77 | 112.2% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Underperform | 25 | 12.31 | 103.09% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 120 85 | 14.73 | 477.05% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 74 | n/a | n/a | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 125 | 70.19 | 78.09% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Equal-Weight | n/a | n/a | n/a | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Equal-Weight | 145 | 83.44 | 73.78% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 51 | 103.16 | -50.56% | 6 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 175 | 57.32 | 205.3% | 4 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 13 6 | n/a | n/a | 2 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 7 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 59 54 | 16.45 | 228.27% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 22 | 106.09 | -79.26% | 1 | Jul 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 86 | n/a | n/a | 1 | Jun 30, 2017 |